Antibody-drug conjugates marry the precise targeting of an antibody to a cytotoxic payload. That has the potential to provide a powerful treatment approach to a variety of cancers with less toxicity than systemically delivered chemotherapy. The problem has been producing large quantities of antibody-drug conjugates in a consistent manner where all the pieces are where they belong. Sutro Biopharma has developed a technology platform that allows it to precisely design and consistently manufacture these molecules. We spoke to Bill Newell, CEO of Sutro, about the promise of antibody-drug conjugates, the company’s platform technology, and its lead therapeutic candidates.
Released:
Aug 14, 2019
Format:
Podcast episode
Titles in the series (100)
The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.
